Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Par Drugs and Chemicals's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Par Drugs and Chemicals Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Par Drugs and Chemicals's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Par Drugs and Chemicals's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Par Drugs and Chemicals (NSE:PAR) has a Buyback Yield % of 0.00 as of Jul. 17, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Par Drugs and Chemicals and its competitors. According to the industry distribution chart, Par Drugs and Chemicals ranks #999999 out of 291 companies in the Drug Manufacturers industry.
Is Par Drugs and Chemicals' Buyback Yield % too high?
Par Drugs and Chemicals' current Buyback Yield % is 0.00. Based on the distribution chart, Par Drugs and Chemicals ranks #999999 out of 291 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Par Drugs and Chemicals has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Par Drugs and Chemicals' Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Par Drugs and Chemicals ranks #999999 out of 291 companies for Buyback Yield %. This places Par Drugs and Chemicals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Par Drugs and Chemicals and its competitors. Par Drugs and Chemicals's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Par Drugs and Chemicals stock overvalued right now?
Based on GuruFocus' analysis, Par Drugs and Chemicals (NSE:PAR) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹207.96, compared to a current price of ₹95.03 — trading 54.3% below its estimated fair value. The current Buyback Yield % is 0.00. Par Drugs and Chemicals' overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Par Drugs and Chemicals (NSE:PAR), the current Buyback Yield % is 0.00 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Par Drugs and Chemicals (NSE:PAR) Overvalued in 2026?
Based on GuruFocus' analysis, Par Drugs and Chemicals stock appears to be undervalued.
The current stock price of ₹95.03 is trading 54.3% below its estimated GF Value™ of ₹207.96.
GuruFocus considers Par Drugs and Chemicals to be Significantly Undervalued.
Key valuation signals for NSE:PAR:
Buyback Yield %: 0.00
GF Value™: ₹207.96 vs. price of ₹95.03 (54.3% below fair value)
No single metric tells the full story. See the NSE:PAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Par Drugs and Chemicals Ltd manufactures active Pharmaceutical Ingredients (APIs) and fine chemicals, serving domestic and international markets. Specializing in essential magnesium-based compounds and other specialty chemicals such as Magnesium Hydroxide, Magnesium Trisilicate, Magnesium Carbonate, various grades of Magnesium Oxide, Dried Aluminum Hydroxide Gel, and Sucralfate USP, the Company produces high-quality bulk drugs used in the formulation of finished pharmaceutical products like tablets, capsules, and liquids. Committed to maintaining stringent quality standards and utilizing manufacturing processes, the Company plays a vital role in supplying reliable ingredients that ensure the safety, efficacy, and stability of pharmaceutical formulations internationally.
82GF Score
Get the complete analysis for NSE:PAR
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:PAR has been successfully added to your 
